The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2020
Filed:
Dec. 31, 2017
Applicant:
Arcturus Therapeutics, Inc., San Diego, CA (US);
Inventors:
Kiyoshi Tachikawa, San Diego, CA (US);
Joseph E. Payne, San Diego, CA (US);
Padmanabh Chivukula, San Diego, CA (US);
Assignee:
ARCTURUS THERAPEUTICS, INC., San Diego, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 9/127 (2006.01); A61K 31/685 (2006.01); A61K 31/713 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 9/127 (2013.01); A61K 31/685 (2013.01); A61K 31/713 (2013.01); C12N 15/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/32 (2013.01); C12N 2310/323 (2013.01); C12N 2320/32 (2013.01); C12N 2320/34 (2013.01);
Abstract
This invention provides pharmaceutical compositions containing a UNA oligomer targeted to TTR and a pharmaceutically acceptable carrier. The compositions can be used in methods for treating or preventing TTR-related amyloidosis in a primate. The compositions, upon administering a single dose to the primate, can reduce TTR protein in the primate for a period of days to weeks.